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Abstract
THE CONTRIBUTION OF SARM1 TO AXONAL DEGENERATION IN CNS
INFLAMMATORY DISORDERS
By: Daniel C. Njoku, B.A.

A thesis submitted for partial fulfillment for the degree of Master of Science in the
department of Physiology and Biophysics at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Major director: Unsong Oh, M.D., Associate Professor, Department of Neurology

BACKGROUND: Multiple sclerosis (MS) is an inflammatory disease of the central nervous
system (CNS) that results in demyelination and axonal loss. Efficiently targeting mechanisms of
axonal degeneration in MS has the potential to reduce disability but remains an unmet need.
Prior research has identified the protein sterile alpha and TIR motif containing 1 (SARM1) as a
critical factor that promotes axonal destruction in the program of axonal degeneration known as
Wallerian degeneration. SARM1 inactivation reduces axonal degeneration in a variety of
contexts including traumatic and toxic injury, but it remains unknown to what extent SARM1 is
involved in axonal degeneration triggered by CNS inflammation. METHODS: To test the
hypothesis that SARM1 inactivation will reduce the burden of axonal degeneration associated
with CNS inflammatory disorders, we first induced mice to have EAE and compared
inflammation (CD3) and axonal damage (SMI-31/32, Beta APP) as compared to healthy control
mice. We then studied experimental allergic encephalomyelitis (EAE) in Sarm1 knockout (KO)
and wild type (WT) mice. We used mice hemizygous for the Thy1-YFP transgene to study
axonal damage. Degenerating axons were identified by focal swelling or fragmentation. Beta-
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APP was also used as a marker of axonal injury. RESULTS: EAE mice had greater inflammation
and axonal injury as compared to healthy mice. Sarm1 KO mice are susceptible to developing
EAE, with incidence comparable to WT littermates. Analysis of YFP+ axons and Beta-APP
showed that Sarm1 KO mice had axonal damage reduced compared to WT littermates.
CONCLUSION: Sarm1 is highly expressed in the brain. Preliminary data suggest that SARM1
inactivation may minimize axonal degeneration in CNS inflammatory disorders such as EAE.
Further studies are needed to confirm the long-term benefit.

1
INTRODUCTION
Epidemiology
MS is a nervous system disease that results in demyelination and axonal loss, which can lead to
many devastating effects and a drastic adjustment in lifestyle for those who suffer from the
disease. The prevalence of MS is highest in the continents of Europe and North America, with a
prevalence rate of over 50 per 100,000 people, while it is lowest in South America and Africa,
with a prevalence of less than 5 per 100,000 people (1). In recent years, MS has increased in
prevalence worldwide. A 2013 report by the Multiple Sclerosis International Foundation (MSIF)
and the World Health Organization (WHO) states that the number of people with MS increased
from 2.1 million to 2.3 million (2). The reported increase in prevalence is due to factors such as
an increase in survival rates of those who have the disease due to improved health care(2). MS
ends up being very costly to patients specifically and to society at large. According to systematic
reviews of MS costs, drug costs are the primary reason for high price among those who are
dealing with a benign form of the disease, while those who are suffering from a more severe
form has more of the cost contained in indirect expenses, such as lost productivity from missing
work and school (3) (4). MS decreases the lifespan by about an average of 10 years (5) (6), but
mortality rates for those who have MS have been declining over the last couple of decades
because of improvement in treatment (5) (7). Other chronic diseases such as depression and
diabetes have been associated with increasing the chance of mortality from MS (5).
Etiology
MS is an autoimmune disease of the CNS based on genetic and experimental evidence
suggesting that both T-cells and B-cells may have roles in causing the phenotype through
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activation and attack of self-antigen (8). The primary pathology of the condition is a gradual
degradation of the axon and the myelin sheath brought on by autoimmunity (10) (11). This
axonal loss has many consequences for the individual, including irreversible neurological
disability, loss of memory, speech disability, and tremors (10) (12). Genetically, MS has been
linked mostly to chromosome 6p21, or HLA-DRB1*1501, which has consistently been found in
studies across populations (13) (14) (15). There has also been new work done that shows that
there may also be influence from chromosome 13q31.3 based on a genome-wide scan of over
500,000 SNPs (16). Genetically, the concordance rate between monozygotic twins is about 2530%, while the rate between dizygotic twins is about 3-5% (15) (17) suggesting a significant
genetic influence on the disease phenotype.
As far as environmental causes are concerned, one primary focus of research has been the role of
viruses. For example, the Epstein Barr Virus have been implicated in MS progression (18).
Patients that have MS have been found to have high numbers of EBV antibodies in their blood
(9). Depending on the time in one’s life course, specific factors, such as smoking and Vitamin D
intake, may have more an impact on other factors in MS progression (18) (19). Demographically,
MS is more likely to affect those of Caucasian descent(20) (21). Other studies have shown that
MS incidence in minority population may be underestimated due to factors such as cultural and
socio-economic barrier for access to healthcare, as well as a long-standing problem with
underrepresentation in clinical trials in general (20) (21).
Diagnosis and clinical course
In 1965, George A. Schumacher proposed the first criteria for MS diagnosis (22). Patients were
diagnosed clinically as to having “clinically definable, probable, or possible” MS based on how
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many of the six points on the measures were proven to be true (22). The six points for the
Schumacher criteria were:
1. Age of onset between 10 and 50 years
2. Objective neurological signs present on examination
3. Neurological symptoms and signs indicative of CNS white matter disease
4. Dissemination in time: two or more attacks separated by a month or progression in
symptoms for at least six months
5. Distribution in space: two or more noncontiguous anatomical areas
6. No alternative clinical explanation

The criteria for diagnosing MS has changed over time due to the advent of new technology that
can detect anatomical changes in the CNS (22). Poser’s criteria modified Schumacher’s
measures by incorporating paraclinical evidence found through evoked potentials or
neuroimaging (22). W.I. McDonald published the most current standards in 2000, which has
undergone two revisions since then, with the recent one in 2010 (22) (23). The McDonald
criteria sought to get rid of the “probable” diagnosis and incorporate the use of MRI,
cerebrospinal fluid (CSF) evaluation, and evoked potentials (23). Establishment of the
McDonald Criteria has allowed for a higher diagnostic rate than there was previously (23).
Common symptoms of MS include vertigo, mood disorder, pain, sensory disturbance, and
fatigue (24). Clinically isolated syndrome (CIS) is a group of symptoms that are typically present
at the onset of MS and include optic neuritis, limb weakness, and paresthesia (25). CIS usually
lasts for 24 hours or longer and is the first sign of MS caused by neuroinflammation (26). CIS is
clinically diagnosed and evaluated (27). If the MRI doesn’t show definitive changes in brain
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structure, then studies such as assessing the CSF for IgG infiltration and evoked potentials are
used (27). MS maybe confused with neuromyelitis optica (NMO), an inflammatory disease that
results in visual loss, and acute disseminated encephalomyelitis (ADEM) a form of
neurodegeneration that is present in children,based on similarities in clinical presentation (26).
Therefore, the Wingerchuk criteria were created for NMO and the magnetic resonance imaging
in MS (MAGNIMS)criteria was created for ADEM (26).
MS has four unique clinical progressions: Relapsing-Remitting MS (RRMS), Primary
Progressive MS (PPMS), Secondary Progressive MS (SPMS), and Progressive Relapsing MS
(PRMS) (28) (29) (Figure 1). RRMS is the most common type, which presents in 85% of MS
patients. RRMS is characterized by periods where the disease symptoms occur for a brief period
before relapsing for a specified period until the next relapse. PPMS has a course of gradual
deterioration and occurs in about 10-15% of MS patients (30). SPMS patients have episodes of
symptoms initially, but then the symptoms gradually progress (30). The last type, PRMS, is
found very rarely in the population and is characterized by a slow progression of the disease over
time with occasional relapses (30). Presentation of MS can be related to age, like those who
develop the disease at age 60 or above have a higher chance of developing a more progressive
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form (PRMS, PPMS, SPMS) (31).

Figure 1: The four different clinical progressions of MS (29)

Imaging
As was previously stated, MS results in demyelination of axons through inflammation (10). The
used of imaging has informed researchers about MS pathology and effects. Magnetic resonance
imaging (MRI) has played a significant role because of its ability to detect lesions that
disseminate in space and time (22) (32). MRI is also useful because it is very responsive to
changes in lesions in MS patients (32). It uses protons to assess lesion damage, normalappearing white matter damage (NAWM) damage, and gray matter damage (32). However,
conventional MRI has limitations. Clinical assessment and MRI measures are not always related
(32). Another limitation is the lack of ability to identify substrates in individual lesions (32). For
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example, inflammation, demyelination, and remyelination all appear similarly on MRI dual-echo
images (32). Therefore, it is harder to assess tissue damage. Modifications such as Magnetization
Transfer (MT) MRI, diffusion-weighted MRI, and proton MR spectroscopy have been used to
find lesions that MRI could not detect (32). MT MRI uses a signal MT ratio (MTR) between free
moving protons and protons which are restricted in movement to detect for axonal injury (32).
Diffusion-weighted MRI uses the difference in diffusion rates between biological tissues and of
water to calculate the apparent diffusion coefficient (ADC) (32). Higher ADC numbers can
signify damage (32). Proton MR spectrometry uses decreases in N-Acetyl group levels as a
signifier of demyelination (32).
Two other imaging techniques to detect anatomical changes are spectral-domain optical
coherence tomography (SD-OCT), which uses head scanning to develop a thickness map of
retinal eye tissue, and microperimetry (MP), a technique that produces a spectral map that can
determine changes in retinal thickness (33). Optic neuritis (ON) is the first sign of MS in a fifth
of MS patients (33). One study found that the volumes of the ganglion cell complex (GCC),
retinal nerve fiber layer (RNFL) thickness and macular volume of the retinal ganglion cells
(RGC) were reduced in MS patients as compared to healthy control patients (33). The study also
a correlation between GCC volume and RNFL thicknes, showing that the ON can affect similar
parts in a similar manner (33).
Pathology and pathophysiology
Autoimmunity and inflammation
MS is a neurodegenerative disease caused by an autoimmune response. The activation or triggers
for this immune response are not well understood, but there is considerable data on the
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significant parts of the autoimmune attack. MS has been long thought to be a CD4+-initiated
autoimmune disease, with myelin-specific T-cells causing early demyelination that leads to
axonal damage and neurological disability (34). The main T-cells involved in the MS phenotype
are T 1 and T 17 (8) (34). T 1 cells produce cytokines such as IFN-γ and TNF-α, which result in
H

H

H

a pro-neurodegenerative immune response (35). T 17 cells have the best ability to cross the
H

blood-brain barrier of all the CD4+ T-cells because of the high expression of cytokine IL-17 (35)
Once TH17 enters the CNS, it can cause damage to neurons through the secretion of granzyme B
(34) (35). In the EAE model, there is evidence that T 1 and T 17 cells can be isolated in the CNS
H

H

after crossing the blood-brain barrier (BBB) (35). (8). There have been a number of
immunosuppressive therapies that have been or are being developed to reduce T cell
proliferation. Mitoxantrone is FDA-approved for immunosuppression (8). It works by decreasing
the number of active T-cell lymphocytes (8). IFN-beta works by decreasing T-cell cytokine
production (8).
CD8+ T-cells also play a role in MS (8) (35) (36). CD8+ T-cells were found in the active lesions
of patients with MS, with high MHC Class I expression (8) (35). Also, the amount of CD8+ Tcells found in the lesions correlated with the amount of axonal damage (36). CD8+ T-cells that
are activated by myelin proteins such as MBP or PLP has been shown to cause damage to
neurons (36). CD8+ T-cells that are reactive against CNS tissue are interesting because they can
escape tolerance induction in the thymus (36). However, CD8+ T-cells have therapeutic
opportunities as well, as they can be directed against myelin-specific CD4+ T-cells to kill them
(36).
The adaptive immune response in MS is not only limited to T-cells, as plasma cells and their
antibodies also play a role in the pathophysiology of MS. From the analysis of patients that have
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MS, but there is also evidence of lesions containing autoreactive B-cells and antibodies (8) (37).
There is also evidence of oligoclonal bands from those patients that show that a limited number
of B-cells is generating the immune response (8) (37) (38). Also found in these lesions are
cytokines that function in B-cell development such as B-cell activating factor(BAFF) (38). From
the evidence of studying EAE in mice, B-cells are activated by a myelin antigen, such as MOG
(8) (37). After activation, B-cells produce antibodies (mainly IgG) that attack axons and myelin
(8). There has been evidence that suppressing autoimmune B-cell activation and development
can work to alleviate MS symptoms. One therapy being developed against autoimmune B-cells is
an anti-CD20 treatment that disrupts immature B-cell growth and proliferation, which reduces
the number of immunoglobulins in lesions in MS (37) (38). Patients with MS also present with a
high concentration of antibodies in the cerebrospinal fluid, mainly IgG complexes (8).
Furthermore, use of immunosuppressants such as IFN-β, mitoxantrone, and glucocorticoids for
MS has been shown to reduce inflammation in patients (8), proving to be a valuable way to limit
the effects of neuroinflammation.
Other cells in the CNS also play a role in MS pathology. Usually, glial cells such as astrocytes
and microglia perform essential functions in the CNS. Astrocytes help regulate the concentration
of neurotransmitters and maintain the BBB, while microglia are the phagocytes and antigen
presenting cells (APC) of the CNS (39) (40). However, in response to neural insult or injury,
glial cells undergo a reactive change that is termed gliosis (41). Astrocytes undergoing gliosis
have many damaging effects including antigen presentation, production of nitric oxide (NO),
production of pro-inflammatory cytokines, and disruption of axonal metabolism (39). There are
less tight junctions maintaining the BBB because of a decrease in tight junction proteins such as
claudin 5 (39). Astrocytes also are responsible for forming glial scars that interfere with the
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remyelination process (39) (42). Glutamate buffering by astrocytes decreases after injury (42).
Their reduced ability to uptake glutamate causes damage to axons as well through the increase in
calcium influx by activating NMDA/AMPA receptors (42). Microglia are also more active and
increase in proliferation in MS. Microglia mainly damage oligodendrocytes through the
production of NO and reactive oxygen species (ROS) (43). Some studies show that microglia
may precede the initial T-cell response in MS and are more prominent during the chronic phases
of MS (44). Most microglia that are damaging are of the M1 subgroup, while the M2 subset is
said to be anti-inflammatory (39). M1 microglia have cytotoxic properties, helping to destroy
oligodendrocytes while producing cytokines such as TNF-α. M2 microglia work to promote
remyelination of neurons (39) (45).
BBB disruption
The BBB is also disrupted in MS, as a more permeable BBB can often be a sign of MS
development (46). Usually, the BBB is composed of endothelial cells and proteins that form tight
junctions to keep most solutes out of the CNS (47). It also acts as a regulator for solutes such as
oxygen and carbon dioxide to flow down their respective concentration gradients by passive
transport (47). Nutrient, drug and protein passage through the BBB is tightly regulated through
different channels (47). Also, the BBB protects the CNS from leukocyte infiltration (49).
Astrocytes are essential in forming tight junctions between endothelial cells and supplying TGFβ, FGF, and GDNF to these cells as well (48). In MS and other neuroinflammatory diseases, the
BBB is disrupted, resulting in increased trafficking of white blood cells and proteins into the
CNS. (49). It is not precisely clear what may cause increased BBB permeability, but there are
several possible explanations (46) (49). One possibility is that recruitment of lymphocytes by
pro-inflammatory cytokines such as TNF, IL-1, and IL-6 to the BBB resulting in increased
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permeability of the BBB to white blood cells (49). In addition, NO produced by cells such as
microglia can disrupt BBB integrity (49). Another possibility is that cytokines influence the
transport of T and T cells across the BBB (35).T cells have been shown to migrate across the
H1

H17

H17

BBB due to high expression of IL-17 in that area (35).
Demyelination
Demyelination is understood to be the pathological hallmark of multiple sclerosis (50). In the
CNS, myelin is produced by oligodendrocytes and function in saltatory conduction and
metabolic buffering (51). In MS, the immune system becomes autoreactive and begins the
demyelination process (36). Autoantibodies against myelin proteins such as MBP and PLP and
production of NO by activated macrophages actively work to demyelinate the axon (52). The
damage from demyelination appears as lesions, of which there are several types. For example,
the early active plaques contain macrophages containing myelin debris such as MOG and PLP
throughout the lesion and are typically found in patients that are undergoing an acute MS attack,
while inactive lesions have macrophages without myelin products and damaged axons (52).
Specific demyelinating disorders has standard traits such as the formation of lesions and
inflammation. They include Marburg MS, which is very rapid and has large lesion formations in
the brain, and Balo concentric sclerosis (BCS), which has a hallmark of concentric lesions (52).
In addition to the differences in the types of injuries, there are also differences in how the lesions
form (53) (54). Pattern I demyelination is mainly caused by macrophages, while Pattern II
involves both macrophages, antibodies, and complement (52) (54). There have also been studies
that showed that oligodendrocytes go through apoptosis independent of inflammation, suggesting
that there may be some other mechanism for causing demyelination (53). This pattern of
demyelination is what is involved in Pattern III, while Pattern IV is rare and deals with non-
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apoptotic oligodendrocytes in the peri plaque white matter (PPWM) (52). Demyelinated axons
have been shown to be susceptible to degeneration (53), there is also evidence that there is
axonal loss happening in inactive lesions as well as active lesions (52). There is also the matter
of the differences between demyelination in white matter lesions compared to gray matter
lesions, which are less inflammatory but may contribute significantly to the MS phenotype (52)
(53). Demyelination in the cerebral cortex is more associated with SPMS and PPMS, while
plaques that are considered that have a high number of macrophages in the lesion are more
associated with the acute phase of MS (55).
Remyelination is the process where axons are re-covered in myelin following demyelination
(56). In MS, there is a process of remyelination where oligodendrocyte progenitor cells (OPCs)
remyelinate axons through maturation into oligodendrocytes (56). Specific factors such as Notch
signaling, LINGO-1 expression, and PSA-NCAM expression influence the remyelination
process (56). With acute lesions, it is possible to have substantial remyelination of exposed
axons, although the myelin sheaths will be thinner (56). Microglia also help with the
remyelination process by producing cytokines to help with OPC differentiation (40). With
chronic lesions, it is highly possible for remyelination to fail because the environment will be
less conducive for oligodendrocytes to produce myelin after autoinflammation (52) (56) (57).
Remyelination in the later stages is mostly confined to the outer edge of the lesion (52) (56) (57).
Astrocytes also interfere with remyelination due to glial scarring that happens after injury (42).
Axonal injury
The result of demyelination and autoimmune attack in the CNS is the gradual loss of axons (58)
(59). Axonal density loss during MS is estimated to be around 20% and can affect any part of the
CNS (58). Also, the reduction of spinal cord cross-sectional area is determined to be about 25-
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37% due to that axonal loss (58). Axonal density loss varies from person to person but gradually
increases as the disease progresses (58). The damage from axonal injury can lead to permanent
disability, with patients developing fatigue, memory loss, and cognitive impairment (60) (61).
The damage to axons results in impaired transport of proteins and organelles, as well as
swellings that develop as a result (61). While axon loss is correlated to auto-inflammatory
activity, evidence for any direct attack on the axons themselves has been less than sufficient (62).
One way that axons can be damaged is through glutamate excitotoxicity that leads to sodium and
calcium to accumulate inside of the axon (63). Calcium is of interest because of its ability to
activate calpains, which degrade the cytoskeleton of axons (52) (60) (63). Increased calcium
buildup has also been studied for its effect on mitochondrial dysfunction. As was discussed
previously, demyelination is another factor in axonal loss. With demyelination leading to a
redistribution of ion channels leading to metabolic dysfunction in the axon (53). There is also
evidence that axonal injury is independent of demyelination. For example, there has been
evidence of axonal loss in mice that that had cortical demyelination later in the disease course
(61). Also, gray matter lesions experience axonal loss in areas that aren’t being actively
demyelinated (61).
One of the ways that axonal damage can be identified is by using a marker such as beta amyloid
precursor protein (β-APP or Beta-APP). β-APP is highly expressed in neurons (axon, dendrites,
and the soma), as well as in vesicles (64). β-APP is transported through the axon using fast
anterograde transport by associating with kinesin (64) (65). In autoimmune diseases such as MS,
there is a higher expression of APP in neurons affected by MS compared to healthy tissue, and
that expression seems to be independent of demyelination (58).
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Another way to assess axonal damage is through the expression of non-phosphorylated
neurofilament H. SMI-32 is a monoclonal antibody that binds to non-phosphorylated
neurofilament H, which can help signify axonal damage. Neurofilament H is the heavy subunit
of the neurofilaments, along with neurofilament L (light) and neurofilament M (medium) (67).
Neurofilament H is usually phosphorylated at the head domain of the neurofilament, and at the
lysine-serine-protein (KSP) motif in the tail domain (66) by MAPKs and dephosphorylated by
protein phosphatases such as PP2A (66). Phosphorylation can help to manage subunit interaction
and resistance to cleavage (66). When the axon is demyelinated, there is an increase of nonphosphorylated neurofilament H expression (62). Also, there has been evidence that axonal
transection leads to a rise in free Neurofilament L and Neurofilament H in the CNS (67).
Wallerian degeneration
Wallerian degeneration is the process of the axons, after injury or disruption of transport, of
gradual axonal loss (68). It used to be thought of a process that was passive at first, but test with
transgenic mice that have the Wallerian degeneration slow protein (Wld ) have led researchers to
s

believe that is a destruction program than causes that axon to break down(69). Similar “dyingback” forms of axonal degeneration happen in other neuronal disorders such as Alzheimer’s (69).
Wallerian degeneration has been a focus of research for its ability to be delayed, with the
possibly of retaining axonal function.
With Wallerian degeneration, there is a latent period (from 4-6 hours in vitro, up to 36 hours en
vivo) where active fragmentation of the axon does not occur (68). During that latent period, the
axon can be protected from irreversible loss by safeguarding its NAD levels (68). There was a
study that showed that a rapid increase in NMN, a precursor to NAD, can trigger Wallerian
degeneration (70). Wallerian degeneration has been shown to be tied to NAD metabolism inside
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the axon, where the rapid loss of NAD interferes with processes such as glycolysis in the axon
(68). During the latent period, the NMNAT isoform in the axon (NMNAT2) that would usually
work to replenish NAD by combining ATP and NMN to produce NAD is rapidly depleted after
injury (68) (71). The Wld protein has an NMNAT domain (NMNAT1) near the N-terminus that
s

has the same functionality as a regular NMNAT protein, signifying that Wld has a similar
s

neuroprotective function (68). After this latent period, the axon continues with rapid
demyelination and axonal degeneration (68). The activity of Wld after axotomy can delay the
s

axonal degradation process by 2-3 weeks (68). The Wld protein has an N16 moiety and a Ube4b
s

protein as well, although there is uncertainty about what role each of those play in axon
protection (71).
Depending on where the injury occurs, Wallerian degeneration can be beneficial or harmful. In
the peripheral nervous system, Schwann cells work right after neuronal damage to remove
myelin debris so that the axons can regenerate (72). The Schwann cells also produce laminin so
that the axons can be remyelinated and neurotrophic facts such as NGF are also secreted (72).
Also, an inflammatory cascade is produced by activated macrophages to clear the myelin (72).
The cascade produces pro-inflammatory cytokines and chemokines soon after injury (TNF-α, ILβ) from the Schwann cells and macrophages then produces pro-inflammatory cytokines such as
IL-6 from the macrophages to help promote re-growth of neurons (72).
In the CNS, there is evidence that the Wallerian degeneration is more harmful to long term
axonal health (72). As opposed to the PNS, the CNS is an immune privileged site, usually
protected from the inflammation generally by the BBB that could help clear myelin debris (72).
At the same time, the microglia that are activated in the CNS are pro-inflammatory (M1) cause
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damage by producing reactive oxygen species (ROS) that demyelinate and damage axons (40)
(72).
SARM1
SARM1 is a member of the MyD88 family of TLR adaptors (MyD88, TRIF, TRAM, and Mal)
(73). It is also known as MyD88-5 (68) (70) (74). The gene is located on chromosome 17q11 in
humans and encodes 690 amino acids (75). The SARM1 protein is highly expressed in neural
tissue and is associated with the outer mitochondrial membrane (68). The protein is highly
conserved among species such as zebrafish (Danio rerio), horseshoe crab (Limulidae), and
nematodes (C. Elegans) (73). Cluster analysis between Human, Drosophila Melanogaster, and
C. Elegans show that the HEAT/Armadillo repeats in the SAM domain are conserved (75). One
of the earliest model organisms for SARM1 testing was Drosophila Melanogaster, with the fruit
fly homolog dSarm shown to promote axonal degeneration (76). SARM1 function has also been
studied in mice (Mus Musculus) in various contexts such as axonal injury and kainic acid (KA)
expression(68) (76). Kainic acid is used to induce excitotoxicity in RGC’s, thereby leading to
axonal destruction (76) SARM1 depletion resulted in preserving retinal nerve structure by
attenuating for KA (76). Figure 2 shows the domains of the protein (68).
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Figure 2: Theoretical figure and activation for SARM1. SARM1 is usually autoinhibited by the
N-terminal domain. After injury, SAM domains multimerize and the TIR domains are activated.
The multimerized TIR domains go out to activate effectors that deplete NAD+ (68).
SARM1 in inflammation
SARM1 has been studied for the different roles it plays in inflammation. Depending on the
context, it can either activate or deactivate inflammation. Unlike the other members of the
MyD88 family, SARM1 does not activate the NF-κB pathway but enables the MAPK pathway
through its TIR domain activating MKK4 through ASK, which goes on to activate JNK and p38
and result in expression of genes involved in the immune response (77) (78). Blocking
inflammation by deleting MKK4 or using AKT to antagonize MKK4 has neuroprotective effects
(68). JNK also works to cause axonal degeneration by targeting stathim 2 (SGC10), a
cytoskeletal protein, for degradation (68). That results in eventual degeneration of the whole
axon (68). Figure 3 shows how SARM1 upregulates JNK and p38 expression while suppressing
TRIF dependent signaling that relies on stimulation of TLR 3/4 inside a CD8+ T-cell (73) (77).
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SARM1 also helps stimulate TLR7/9 mediated apoptosis in neurons though localization to the
mitochondria and subsequent mitochondrial accumulation inside neurons (79). In a study by
Szretter et. Al, mice were infected with West Nile virus (WNV)(80). SARM1 deficiency worked
to decrease TNF-α production in the CNS, leading to higher mortality in mice infected by WNV
(80). SARM1 deficient mice also had lower microglia activation (80) (81).
SARM1 can also work to decrease cytokine production (77) (81). SARM1 in the neuron can
work to decrease cytokine production by blocking the TRIF-dependent pathway and instead
activate the MKK4 pathway that results in the activation of Bax, an effector of apoptosis (77).
SARM1 knockout mice were shown to have higher levels of IL-6 and IFN-Beta in embryonic
neurons (81). In adult neurons, SARM1 knockout mice have higher levels of IL-1-beta and IL12b (cytokines of the NF- κB pathway) (81).
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Figure 3: SARM1 activates the JNK/p38 pathway in CD8+ T-Cell. SARM1 activates
ASK1, which phosphorylates MKK4 in the MAPK pathway. JNK and p38 are activated
and go to the nucleus to activate cytokine production. SARM1 also inhibits the TRIFdependent pathway from TLR4 signaling (77).
SARM1 in axonal degeneration
SARM1 causes axonal damage by NAD+ cleavage (68) (82). The SARM1 protein is usually
auto-inhibited by its N-terminal domain, but following axonal injury, the SAM domains allow
for dimerization of SARM1, leading to activation of its effector function that results in cleavage
of NAD (68) (82). Lower NAD+ levels can result in axonal metabolic dysfunction, resulting in
an influx of Ca2+ and subsequent activation of calpain (52) (60) (63) (68). Research done in the
nematode found that cleavage of NAD required dimerization of the TIR domains in C. elegans
(TIR-1), although the deletion of NAD+ was not as robust as in human SARM1 (82). Neurons in
mice that have SARM1 deleted has ATP and NAD levels that remain at normal levels, and as a
result have axons that can survive longer, like the effects of Wld (82). Also, axons have an
s

endogenous NMNAT (NMNAT2) that can inhibit SARM1 by synthesizing NAD+ (68). Lower
NAD+ levels in the axon because of NMNAT2 loss or inactivation has been theorized to activate
SARM1 (68) (82). Another way that SARM1 is activated is explained by the NMN hypothesis.
According to the hypothesis, higher NMN levels are responsible for triggering SARM1 (68).
NMNAT2 works to consume NMN and ATP and make NAD+, thus preventing activation (68).
Figure 4 shows how SARM1 functions to trigger axonal degeneration (68).
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Figure 4: SARM1 axonal degeneration pathway. As SARM1 is activated, TIR
dimerization results in NAD+ depletion and MAPK activation. Eventually, ATP is
depleted, and the axon begins to break down.NMNAT2 loss also results in SARM1
activation. (68)
Experimental allergic encephalomyelitis
Experimental allergic encephalomyelitis is an animal model of MS that has been used to
understand possible causes and effects of the disease (83). It has also been used to test treatments
for MS, such as using IFN-β or glucocorticoids for immunosuppression (83). The disease was
first studied in primates but has since included other animals such as mice and guinea pigs (53)
(83). Unlike MS, the animal must be inoculated with a myelin antigen (usually MBP or MOG )
35-55

and adjuvant (usually CFA) to produce the EAE phenotype (83). Once the animal has been
inoculated, EAE develops as the animal is monitored over several days. There are similarities be
between EAE and MS. In EAE and MS, there is increased T-cell infiltration and demyelination,
increased adhesion molecule expression, and increased cytokine production (8) (84) (85). There
are differences between EAE and MS that are important to note, such as the heterogeneity of
disease progression and the heterogeneity of effects across species (8). However, EAE has been
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proven to be an excellent way to study the effects of MS. There has been prior research that has
used SARM1 expression to research nerve protection in mice and other animals (68). In the
mouse, the gene for SARM1 is found on chromosome 11 (86). Inactivation has shown some
evidence of axonal protection and lower inflammation. SARM1 silencing in mice was shown to
lower axonal degeneration in the retinas (77). SARM1 inactivation leads to preserved NAD+
levels in Drosophila flies (82).
Hypothesis
We hypothesize that SARM1 works to cause breakdown of axons by interfering with the local
metabolism of the axon after the autoimmune attack and that axons can be rescued by
inactivating the protein genetically. Using EAE as a model for MS, we aim to understand how
SARM1 inactivation affects axonal degeneration. Preliminary data has shown a modest reduction
in clinical EAE score over the first couple of weeks post-induction and a lower clinical score
overall.
Specific Aims
S1: Establish EAE pathology
EAE will be induced in several mice using CFA+MOG33-55. Clinical scores will be assessed
daily over the course of a six-week period. IHC will be used to determine inflammation (CD3)
and axonal health (Beta-APP, SMI-31/32) in healthy and EAE mice.
S2: Assess SARM1’s impact on axonal integrity
The specific aim is to examine the effect of SARM1 on axonal degeneration in the context of
EAE. End-point PCR and qRT-PCR will be used to assess genotype and gene expression.
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Western Blotting and ICH will be used to validate antibodies. YFP expression and Beta-APP
expression will be used to measure the amount of axonal degeneration to quantify SARM1’s
impact of axonal damage.

METHODS
Mice
Sarm1 KO (B6.129X1-Sarm1tm1Aidi/J) mating pairs were obtained from Jackson Laboratories
(Bar Harbor, ME). A breeding colony of Sarm1 KO mice was then maintained in-house. A
heterozygote mating scheme generated Sarm1 KO and WT littermates for the EAE experiments.
Thy1-YFP (B6.Cg-Tg(Thy1-YFP)HJrs/J) mating pairs were a kind gift from John Povlishock.
The Thy1-YFP mice express yellow fluorescent protein (YFP) at high levels in motor and
sensory neurons, as well as subsets of central neurons. Axons are brightly fluorescent all the way
to the terminals. A breeding colony of Thy1-YFP mice was maintained in-house. To generate
Sarm1 KO mice that express YFP in neurons, we crossed mice hemizygous for the Thy1-YFP
transgene and Sarm1 KO mice to yield Thy1-YFP/Sarm1+/- mice. Thy1-YFP/Sarm1+/- breeding
pairs were maintained to generate Thy1-YFP/Sarm1-/- and Thy1-YFP/Sarm1+/+ littermates for
EAE experiments. All mice were C57BL/6 background.
EAE
EAE was actively induced by injection of myelin oligodendrocyte peptide (MOG ) in complete
35-55

Freund’s adjuvant and injection of pertussis toxin. Sham control mice were injected with
complete Freund’s adjuvant without MOG35-55. Clinical severity was scored according to a
standard 5-point scale: 0 = normal, 1 = limp tail or loss of righting reflex, 2 = limp tail and loss
of righting reflex, 3 = partial hind limb weakness, 4 = hind limb paralysis, 5 = moribund or
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death. The cumulative clinical score was calculated as the sum of daily clinical scores over the
course of observation.
DNA Purification
DNA was purified from tissue using the DNeasy Kit (Qiagen) according to manufacturer’s
protocol. Tail clippings were digested in 180 µL of buffer ATL and 20 µL of proteinase K and
kept overnight at 56℃. 200 µL of Buffer AL and 200 µL of 100% ethanol was added to tail
tissue. The product was then vortexed. The mixture was then pipetted into a DNeasy spin column
in a two mL collection tube. The mixture was centrifuged at 6000 x g for 1 min at room
temperature. The spin column was placed in a new 2 mL collection tube. 500 µL of Buffer AW1
was then added. The product was centrifuged at 8000 rpm for 1 minute at room temperature. The
spin column was then placed in a new 2 mL collection tube. 500 µL of Buffer AW2 was added.
The product was centrifuged at 14,000 rpm for 2 mins at room temperature. The spin column
was then placed in a 1.7 mL microcentrifuge tube. 200 µL of Buffer AE was added to the
mixture to elute the DNA. The product was then incubated for 1 min at room temperature. The
mixture was centrifuged at 8000 rpm for 1 min at room temperature. Concentrations were
measured spectrophotometrically on a BioTek plate reader.
Sarm1 genotyping
Sarm1 genotyping was performed by PCR. The reaction mixture comprised of DNA, PCR
mastermix (Amplitaq Gold 360 MasterMix, Applied Biosystems) and primers. Sarm1 knockout
forward and reverse primers were CTT GGG TGG AGA GGC TAT TC and AGG TGA GAT
GAC AGG AGA TC, respectively. Sarm1 wild type forward and reverse primers were GGG
AGA GCC TTC CTC ATA CC and TAA GGA TGA ACA GGG CCA AG, respectively. Each
PCR reaction well contained 12.5 μL of mastermix, 2.5 μL of forward and reverse primers and
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10 μL of DNA sample (50 ng). A non-template control well was included for each assay. The
Venti Thermal Cycler was set with the Amplitaq Gold 360 run protocol for a 25 𝜇L reaction: The
samples were heated for 10 minutes at 95℃. Then, they went through 40 cycles of initial
denaturation at 95℃ for 30 second, primer annealing at 60℃ for 30 seconds, and extension at
72℃a at 60 kb/second. The final extension was for 7 minutes at 72℃. The samples were cooled
at 4℃ after the final extension was complete.
The PCR product was analyzed by gel electrophoresis. 50 mL of 2% agarose with 5 µL of Gel
Red was poured into a beaker, then into a DNA Plus electrophoresis well and allowed to solidify
with 2 combs placed inside the gel. 1x TBE buffer (0.089 M Tris Base, 0.089 M Boric Acid,
0.002 M Disodium EDTA·2H O) filled the well so that the gel was covered. 5 µL of ddH O was
2

2

mixed with 2 µL of Blue/Orange 6x loading dye on parafilm. 5 µL of PCR product or the NTC
was mixed with ddH O and 6x loading dye and loaded into the gel. The gel ran at 80 V for about
2

an hour. The gel image was taken with an Aplegen Imager.
RNA Purification
RNA was purified from mouse tissue. Following euthanasia, brain, liver, kidney, spleen, and
testis were harvested from mice and placed in a 1.7 mL microcentrifuge tube with 350 µL of
RNAlater (Qiagen) was added to preserve RNA for later use. Tissues were lysed using a
TissueLyser LT. Briefly, stainless steel beads were added to each tube. 1 mL of QIAzol reagent
was then added to each tube. Tissues were lysed for 5 min at 50 Hz and then left to stand for 3-5
minutes. The stainless-steel beads were then discarded using a small spatula. Chloroform (200
µL) was added to each tissue sample inside the fume hood. The tissues were then centrifuged at
12,000 x g for 15 minutes at 4℃. After centrifugation, the mixture was separated into an aqueous
top layer, a white interphase layer, and a pink organic layer. About 400 µL of the aqueous layer
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was transferred to a 1.5 mL RNAse free tube containing. 400 µL of 100% ethanol. The resulting
mixture was then transferred to RNeasy mini spin columns (Qiagen) for RNA purification
according to manufacturer’s protocol. The columns were placed on a vacuum manifold. The
columns were washed with 700 µL of buffer RW1, 500 µL of buffer RPE, and 500 µL of buffer
RPE, sequentially, using the vacuum after each addition. After the washing, the columns were
placed in 2 mL collection tubes. The columns were then dried by centrifugation at full speed
(21,100 x g) for 1 minute. The columns were then placed in 1.5 mL collection tubes. 50 µL of
RNAse-free water was then added to the columns to elute the RNA. The columns were then
centrifuged at 8000 x g for 1 min. RNA concentration was measured spectrophotometrically
using a BioTek plate reader. The RNA samples were stored in a -80℃ freezer until later use.
Quantitative reverse transcriptase (qRT)-PCR
Sarm1 RNA expression was measured by real-time RT-PCR. TaqMan mastermix, Actb
primer/probe, Sarm1 primer/probe mix (Mm_001308995_m1 Thermo Scientific), which spans
Sarm1 gene exons 1 and 2, Sarm1 primer/probe mix (Mm_00555617_m1, Thermo Scientific),
which spans Sarm1 genes exons 7 and 8, and reverse transcriptase were thawed in PCR/UV box.
Wells were planned out for each RNA sample so that 10 μL of mastermix, 1 μL of each
primer/probe, 0.5 μL of reverse transcriptase and 8.5 μL of diluted sample were added to each
well. A non-template control (NTC) of ddH O was also used for the wells. A working mixture of
2

mastermix and primers was made and aliquoted into wells. Wells were taken into biosafety
cabinet, and RNA was aliquoted into wells. Wells were capped and centrifuged at 1000 rpm for 2
min. The samples were placed into the StepOnePlus Real-Time PCR machine. 2-step singleplex
RT-PCR was run to convert RNA into cDNA and to amplify cDNA expression: WT Spleen was
set as the reference sample, and Actb was used as the endogenous control for the comparative C

T
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experiment. Samples were heated from 25℃ to 95℃ for 10 minutes in the holding stage and
then ran through 40 cooling and heating cycles between 60℃ and 95℃ for 1 minute each.
Fluorescence was measured using the StepOnePlus machine.
Western Blotting
WT brain, WT liver, Sarm1 KO brain, and Sarm1 KO liver protein samples were diluted to 6
mg/mL using cold lysis buffer (RIPA buffer, ThermoScientific) and 1x Protease Inhibitor
Cocktail). The samples were further diluted to 3 mg/mL by 100µL working Lammeil Buffer (950
µL of 2x Lammeil Buffer and 50 µL of 2-mercaptoethanol). The samples were resolved in a
Mini Protean Precast gel (10-well, 30 µL per well) at 200 V for 35 minutes. The was prepared
for transfer of the protein. The product was then transferred to a nitrocellulose membrane
through the Bio-Rad Trans-Blot Turbo Transfer System with 1x turbo blot transfer buffer (50 µL
5x Turbo Blot Transfer Buffer (BioRad), 50 µL of 200 proof ethanol, and 150 µL of deionized
water). The membrane was then agitated with Ponceau S for 10 minutes, washed with deionized
water, then imaged with an Aplergen imager. Then the membrane was washed with PBS-Tween
3 times for 5 minutes each. The membrane was then blocked with PBS-Tween-5% milk for 30
minutes. The membrane was then stained with the diluted primary antibody (Rat Anti-SARM1,
Biolegend, 1:1000 in PBS-Tween) and agitated at 4℃ overnight. The membrane was washed
with PBS-Tween 3 times for 5 minutes each. The membrane when stained with secondary
antibody (CARt-HRP, Santa Cruz, 1:5000 in PBS-Tween) and agitated for 45 minutes at room
temperature. The membrane was washed with PBS 3 times for 5 minutes each. Less than 1 mL
of Millipore immobilon reagent was applied to the membrane. The membrane was then imaged
with an Aplergen imager using the Chemiluminescence setting. The membrane was then stripped
and reblotted for Beta-Actin as an endogenous control. Mouse Anti-ꞵ Actin, (ThermoScientific,
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1:5000 in PBS-Tween) was the primary antibody, while DAM-HRP, (ThermoScientific,1:5000
in PBS-Tween) was the secondary antibody.
Fluorescent Immunohistochemistry
Parts of the mouse CNS were surgically removed from mice and placed in optimal cutting
temperature (OCT) cryopreservative and stored at -80°C. 20 µm sections or 10 µm sections
(SMI-31/32) and using a Lecia CM 1950 cryostat and placed on positively charged slides. The
sections had a PAP border drawn around them after the OCT as trimmed. All sections were
rinsed in 1x TBS (Fisher Bioreagents) after sectioning, after primary antibody application, and
after secondary antibody application 3 times for 5 minutes each. Blocking buffer (970 μL of
TBS, 2 drops of cold skin fish gelatin (EM Sciences #25560) and 30 μL of 10% Triton X-100)
was used for blocking.
Primary antibodies stained for Beta-APP (Rabbit Anti-Beta APP, Thermoscientific, 1:400),
SARM1 (Rat-Anti SARM1, Biolegend, 1:200), NeuN (Mouse unconjugated Anti-NeuN,
Millipore,1:100), SMI-31 (Mouse SMI-31, Calbiochem, Cat No. NE1022, 1:1000), SMI-32
(Mouse SMI-32, Calibiochem, Cat. No. 1023, 1:1000), CD3 (Hamster Anti-CD3, BD
Biosciences, 1:100), and CD31 (Rat Anti-CD31, ThermoScientific, 1:50). Sections were placed
in a 4°C refrigerator overnight for primary staining (60 minutes for CD3/CD31 at room
temperature), and at room temperature for 90 minutes (60 minutes for CD3/CD31) for secondary
staining in a closed, moisturized box. Sections were blocked for 15 minutes before primary and
secondary staining at room temperature. All sections were stained with either primary antibody
or blocking buffer before secondary staining. Secondary antibodies used for this project were
Rabbit IgG Alexa Fluor 594 antibody, Goat Anti-Rat IgG Alexa Fluor 594, Goat Anti- Mouse
Ⓡ

Ⓡ

IgG Alexa Fluor 488, and Goat Anti-Hamster IgG Alexa Fluor 488 (all 1:1000). DAPI
Ⓡ

Ⓡ

27
(Vectashield ) was used as a counter-stain before imaging and coverslips were purchased from
Ⓡ

Corning. Digital images were taken with a Life Technologies imager, then modified using the
™

Fiji program from the NIH (87). Every fifth lumbar cord section was stained for Beta-APP.
Every fifth lumbar cord section was mounted for YFP+ axonal counting. Beta-APP particles and
YFP+ expressing axons were manually counted using Fiji (87).
Antigen Retrieval
Sections were placed in a plastic coplin jar of 40 mL citric acid buffer (pH 6.0). Another plastic
coplin jar was filled with 40 mL of ddH O. The two coplin jars were both placed in a microwave,
2

and a thermometer was placed in the coplin jar that was filled with deionized water. The sections
were microwaved at 525 W with a 45℃-maximum temperature for 7 minutes. The sections were
then removed from the microwave and allowed to sit for 5 minutes. The sections were
microwaved at 525 W with a 45℃-maximum temperature for 5 minutes and 30 seconds. The
sections were then removed from the microwave and allowed to sit for 20 minutes. Afterwards,
the slides were then washed rapidly in 1x TBS 3 times.
M.O.M protocol -SMI-31/SMI32 (Neurofilament H)
Sections were fixed in pre-chilled 100 % methanol for 10 minutes at -20℃ after antigen
retrieval. A working solution of Vector M.O.M

TM

Mouse IgG Blocking reagent (FMK-2201)

was prepared by adding 60 μL of the stock solution to 2.5 mL of TBS. A working solution of
M.O.M

TM

Diluent was prepared by adding 600 μL protein concentrate to 7.5 mL of TBS. The

sections were then washed 3 times in TBS for 5 minutes each. Then each of the sections was
incubated with Mouse IgG blocking reagent for 1 hour. Then the slides were washed in TBS
twice for 2 minutes each. The primary antibodies and were diluted in M.O.M

TM

Diluent. Mouse
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SMI-31 was applied to an EAE lumbar cord section and a healthy lumbar cord section. Mouse
SMI 32 antibody was applied to an EAE and healthy lumbar cord sections. M.O.M

TM

Diluent

was applied to an EAE section as a control. The slides were incubated overnight in a closed,
moisturized box in a 4℃ refrigerator. On the next day, the sections were washed in TBS twice
for 2 minutes each. A working solution of M.O.M

™

Biotinylated Anti-Mouse IgG Reagent was

prepared by adding 10 μL of stock solution to 2.5 mL of M.O.M
™

TM

Diluent. M.O.M

Biotinylated Anti-Mouse IgG Reagent was applied to each section, and the sections were

incubated for 10 minutes. The sections were then washed in TBS twice for 2 minutes each. A
working solution of Texas Red Avidin DCS was prepared by adding 40 μL of stock solution to
2.5 mL of TBS. Texas Red Avidin DCS was applied to each section and incubated for 5 minutes.
The slides were washed in TBS twice for 5 minutes.
YFP axonal counting
+

Axons were manually counted by drawing three vertical lines to contact the axons and then
manually counting the axons at the contact points along the longitudinal tracts using Fiji (87).
Degrading axons were identified by focal swellings or fragmentation along the axon.
Statistical Analysis- YFP and Beta-APP
+

Mann-Whitney tests were used to compare WT (N = 4) and Sarm1 KO (N = 3) mouse littermates
for YFP+ expressing axons, degrading axons, and Beta-APP particles. The p-value calculator for
the test was found on http://astatsa.com/WilcoxonTest/. Statistically significant p-values for this
experiment were p < 0.05.
RESULTS
Sarm1 KO mice
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Sarm1 KO mice were genotyped by PCR. Figure 5 shows the Sarm1 PCR products for the WT,
heterozygote and Sarm1 KO mice. PCR using primers for Sarm1 and WT alleles resulted in
bands near the expected 280 bp and 186 bp, respectively. Sarm1 KO and WT alleles were both
present in heterozygotes.

Figure 5. Sarm1 genotyping by PCR. DNA was isolated from mice tail clippings. End-point
PCR was performed using primers targeting Sarm1 KO and WT alleles. A representative agarose
gel electrophoresis is shown with PCR products for mice homozygous for the WT allele (WT),
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heterozygote (Het), and homozygous for the Sarm1 KO allele (KO). DNA ladder denoting size is
shown on the left.

Sarm1 mRNA expression
Sarm1 mRNA from brain, kidney, spleen, liver, and testis of WT mice were measured by
quantitative reverse transcriptase (RT)-PCR to determine the relative Sarm1 expression among
different tissues. Figure 6 shows Sarm1 gene expression for each tissue type. Sarm1 expression
was highest in the mouse brain, followed by the testis. Sarm1 expression was low in the kidney,
spleen, and liver (Figure 6).

Figure 6: Sarm1 gene expression in different tissues. Genomic DNA was isolated from various
mouse tissue, then quantitative RT-PCR (QRT-PCR) was performed to measure relative Sarm1

31
mRNA expression. Relative quantities (RQ) were calculated using the ΔΔCT method. Actb was
used as the endogenous control. Spleen was used as the reference sample. N = 3 for brain,
spleen, liver, and kidney; N = 2 for testis. Mean (+S.E.M) shown.

To further characterize how Sarm1 gene expression is altered in the Sarm1 KO mice, qRT-PCR
was performed using primers directed against either the 5’ or the 3’ regions of the Sarm1
transcript. One primer/probe set spanned exons 1 and 2 of the Sarm1 transcript, and the other
spanned exons 7 and 8 of the Sarm1 transcript. Figure 7 shows the relative Sarm1 expression in
WT and Sarm1 KO brain using the two Sarm1 primer/probe sets. As expected, WT brains
showed relatively high Sarm1 mRNA expression with primer/probes spanning either exons 1 and
2 or exons 7 and 8. We detected Sarm1 mRNA expression in the Sarm1 KO brain using
primer/probes spanning exons 1 and 2, although at a substantially lower level compared with
WT. Sarm1 KO brains showed no mRNA expression when qRT-PCR was performed with
primer/probe set spanning exons 7 and 8. These results showed that in the Sarm1 KO mice,
exons 7 and 8 of Sarm1 gene are not transcribed, indicating that a truncated Sarm1 mRNA is
produced in the Sarm1 KO mice.
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Figure 7. Sarm1 gene expression in brain tissue based on genotype and probe combinations.
mRNA was either amplified with Sarm1 primer/probe set 1309985 that spans exons 1 and 2 or
Sarm1 primer/probe set 555617 that spans exons 7 & 8. RQ values are shown.

EAE pathology
Initial studies with EAE were aimed at establishing methods to assess pathologic changes
associated with EAE by immunohistochemistry. CNS inflammatory infiltrates were detected by
CD3 immunohistochemistry. Axonal pathology was identified by APP and SMI-31 and SMI-32
immunohistochemistry. EAE was compared with sham or healthy controls.

CD3 immunohistochemistry
CD3 immunohistochemistry was performed to assess inflammation in EAE mice. Figure 8 shows
CD3 immunohistochemistry for EAE and sham control mice. PECAM immunohistochemistry
was performed simultaneously to identify blood vessels. There is more CD3 marker staining in
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the EAE lumbar cord than in the lumbar cord of the sham control mouse, showing CNS T-cell
infiltration in EAE.

Figure 8. Increased CD3 staining in EAE lumbar cord. CD3, CD31/PECAM, DAPI, and merged
images shown. Scale bar = 100μm.

SMI 31/32 immunohistochemistry
Neurofilament H immunohistochemistry was performed using SMI-31 and SMI-32 to assess
axonal integrity in EAE mice. Figure 9 shows SMI-31 immunohistochemistry of longitudinal
sections of the lumbar cords of EAE and the sham control mice. As Figure 9 show, there is
comparable staining, shown in red. Figure 10 shows SMI-32 immunohistochemistry of lumbar
cord of the EAE and sham control mice. Comparing the two pictures shows that there is more
non-phosphorylated neurofilament-H in the EAE mouse.
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Figure 9: Comparable phosphorylated neurofilament H (SMI-31) staining in EAE and healthy
lumbar cords. Representative phosphorylated neurofilament H, DAPI, and merged images are
shown. Scale bar = 100μm.
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Figure 10: Increased non-phosphorylated neurofilament H (SMI-32) staining in EAE mouse.
Lumbar cord sections for EAE and control mice were stained for the axonal marker nonphosphorylated neurofilament-H. Representative non-phosphorylated neurofilament-H, DAPI,
and merged images are shown. Scale bar = 100μm.

B-APP immunohistochemistry
Beta-APP immunohistochemistry was utilized to assess axonal damage in EAE mice. Beta-APP,
DAPI, and multichannel (+YFP) images (Figure 11) of the longitudinal sections of the lumbar
cord of an EAE mouse and a healthy mouse. Comparing the two sets of images shows that there
is reduced Beta-APP particles in the EAE lumbar cord than in the healthy lumbar cord.
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Figure 11: Increased beta-APP staining in EAE lumbar cord. Beta-APP, DAPI, and merged
(+YFP) images shown. 20x magnification.

EAE in Sarm1 KO mice
To study the contribution of SARM1 to clinical illness, EAE was actively induced in Sarm1 KO
and WT littermates. Figure 12 shows the clinical scores for WT and Sarm1 KO mice over a 6week period. Sarm1 KO mice showed comparable scores to WT littermates at the beginning of
the induction but showed lower clinical scores starting around the third week. Overall, Sarm1
KO littermates showed lower mean cumulative EAE clinical scores, although the differences
were not statistically significant (Figure 12).
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Figure 12: EAE was actively induced in Sarm1 KO mice (N = 9) and WT littermates (N = 7).
Mean clinical scores (+/- S.E.M.) for Sarm1 KO and WT littermates (left). Mean cumulative
clinical scores for Sarm1 KO and WT littermates; lines show mean and standard deviation
(right).

Beta-APP immunohistochemistry was used to assess axonal injury in Sarm1 KO and WT mice.
Beta-APP, DAPI, and multichannel images of the lumbar cord sections of WT and Sarm1 KO
mice (Figure 13). We observed that there were less Beta-APP particles in the Sarm1 KO mouse
lumbar cord then there is in WT lumbar cord (Figure 14). We found a P-value of 0.114 at a 95%
confidence level. WT mice had an average of 119.7 particles per section with a standard
deviation of 34.4, and Sarm1 KO mice had an average of 67.8 particles per section with a
standard deviation of 35.5.
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Figure 13. Decreased beta-APP staining in Sarm1 KO lumbar cord. Beta-APP, DAPI, and
merged (+YFP+) images of WT and Sarm1 KO lumbar cords shown. Scale bar = 100μm.
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Figure 14. Beta-APP particle comparison for WT (N = 4) and Sarm1 KO (N = 3) littermates.
More Beta-APP particles were found in the WT littermates than in the Sarm1 KO littermates.
Mean (+S.E.M) shown. Mann-Whitney Test. P-value = 0.114 (W = 1).

To further assess axonal degeneration in Sarm1 KO and WT mice we generated Sarm1 KO mice
and WT littermates that were hemizygous for the YFP gene. These mice express YFP under the
Thy1 gene promoter at high levels in motor and sensory neurons, as well as subsets of central
neurons. Axons were readily identified in longitudinal sections of the lumbar cord in these mice.
Degenerating axons were identified by focal swelling or fragmentation. Thy-1-YFP+ mice
sections were utilized to quantify SARM1’s impact on axonal degeneration. Degrading axons
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and total axons were counted. YFP, DAPI, and multichannel images of the WT and Sarm1 KO
lumbar cords are shown in Figure 15. There was a higher number of fragmented axons in WT
than Sarm1 KO mouse. Figure 16 displays the total number YFP axons in WT and Sarm1 KO
mice, which show that Sarm1 KO mice have a lower amount of YFP expressing axons and
degrading axons. We found P-values of 0.400 for total axons, 0.114 for intact axons, and 0.629
for degrading axons at a 95% confidence level. WT mice had an average of 63.9 axons per
section with a standard deviation of 25.5, and Sarm1 KO mice had an average of 44.9 axons per
section with a standard deviation of 23.6.

Figures 15: Decreased YFP expression and axon fragmentation in Sarm1 KO mouse. YFP,
DAPI, and merged images WT and Sarm1 KO lumbar cord sections shown. Scale bar = 100μm.
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Figure 16: a) Axon counts from WT (N = 4) and Sarm1 KO (N = 3) lumbar cord sections. More
axons found in WT lumbar cords than in Sarm1 KO lumbar cords. Mean (+S.E.M) shown. b)
Intact vs. degrading axon counts from WT and Sarm1 KO mice. Mean (+S.E.M) shown. MannWhitney Test. P-values: 0.400 (total) (W = 3), 0.114 (intact) (W = 3), 0.629 (degrading) (W = 8).

DISCUSSION
EAE pathology
We wanted to assess EAE pathology in mice relative to healthy mice to better understand the
pathology and effects of MS. Inducing mice to have EAE has resulted in mice having higher Tcell counts in CNS tissues (84) (85). Using the T-cell marker for CD3, we were able to show that
EAE induction results in higher CD3 expression (Figure 8). T-cells that infiltrate the CNS has
shown to have neurodegenerative effects through targeting myelin. EAE and MS eventually
result in axonal damage and dysfunction (58) (64). To assess this, we stained for phosphorylated
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neurofilament H (SMI-31), dephosphorylated neurofilament H (SMI-32), and Beta-APP in EAE
and healthy mice. Comparable phosphorylated neurofilament H staining was found between
EAE and healthy lumbar cord (Figure 9). However, increased dephosphorylated neurofilament H
staining was found with EAE induction (Figure 10). Dephosphorylated neurofilament H is a sign
of poor axonal health (64). Beta-APP expression is assessed as a signifier of disrupted axonal
transport in diseases such as MS and Alzheimer’s. We found more Beta-APP particle expression
in EAE tissue as compared to healthy tissue (Figure 11). Understanding the different ways that
EAE manifest in mice was essential for establishing a baseline for SARM1. SARM1 has been
studied both for its role in inflammation and axonal degeneration. Lack of SARM1 expression
has been shown to protect axons (68). Mice with the Sarm1 gene disrupted should have a starkly
different pathology of EAE than those mice that don’t.
SARM1 is primarily found in the brain

We first wanted to validate the genotype of SARM1 of the mice we received from Jackson
Laboratory. End-point PCR was valuable in establishing the Sarm1 genotypes of several
different mice. Figure 5 shows the example of a gel that was ran that had three different
genotypes. Quantitative RT-PCR was performed to measure mRNA expression in various mouse
body tissues. Figure 6 showed SARM1 was more expressed in the brain than in other tissues.
Our data correlates to a previous study by Mink et. Al. that showed that SARM1 is highly
expressed in mouse tissue (86). From previous studies, SARM1 is highly expressed in neurons
and functions in neuronal death (68) (74). Assessing the expression of SARM1 in different
tissues help illustrate the unique role that SARM1 has in axonal pathology. We then wanted to
validate the genotype through quantitative RT-PCR using two different Sarm1 probes (Figure 7).
The neomycin cassette vector in the Sarm1 KO mice targets and replaces exons 3-6 of the Sarm1
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gene (91), so we aimed to compare Sarm1 expression with two different primer/probe sets that
targeted different areas of the Sarm1 gene. We found that there was less expression of Sarm1 in
the KO mouse brain with both primer/probes. Also, the primer/probe set directed against the 3’
end of the Sarm1 showed no amplification in the Sarm1 KO brain. This data appears to be
consistent with the Western Blot analysis found by Ding et. Al (91). Using qRT-PCR was
helpful to assess primer quality as well as gene expression.

SARM1 and axonal degeneration
SARM1 functions to cause Wallerian degeneration through rapid NAD depletion post injury (68)
(82) (88). From the clinical scores of the littermates that were induced to have EAE (Figure 12),
there were comparable clinical scores between the two samples, although the SARM1 KO
littermates showed improvement over time. We wanted to see if we could quantify this effect
through axonal damage markers.
After staining for dephosphorylated neurofilament H (Figure 10) and Beta-APP (Figure 11), we
found that the was a prominent increase in axonal damage EAE mice than in control mice. BetaAPP and dephosphorylated neurofilament H expression increase with damaged axons (89). We
then wanted to see how a Sarm1 KO EAE could reduce axonal damage as comparted to a WT
EAE mouse. Thy1-YFP+ mice were used to quantify axonal injury in a subset of neurons that
express it. We found that there was a higher number of YFP expressing axons in WT mice
compared to Sarm1 mice in total (Figure 16a) and less degrading axons in total (Figure 16b)
although the p-value was not significant between the two samples. When quantifying axonal
damage through B-APP, there was decreased expression in Sarm1 KO compared to WT,
although the difference was not statistically significant. Comparing the healthy lumbar cord
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(Figure 11) and Sarm1 KO (Figure 13) lumbar cord, there is some similarity in Beta-APP
expression. The accuracy in counting the axons and particles can result from having a more
established standard in place for counting. One way to help quantify degrading axons in the
future is to establish a baseline axonal density for all sections. Comparing non-phosphorylated
neurofilament H and fluoromyelin staining for Sarm1 KO and WT lumbar cords will allow us to
understand SARM1’s effect on axonal damage further, while also assessing
demyelination/remyelination.

Conclusions and Future Directions
We found that SARM1 is highly expressed in the brain. From there, we mainly focused on the
axonal degradation effects of SARM1, showing that there is a modest, but not significant,
decline in axonal injury. A future area of study is the role that SARM1 plays in cytokine
production and inflammation. SARM1 activates JNK through the MKK4/MKK7 cascade and
p38 through (68) (77). JNK works to enable TH0 cells into pro-inflammatory TH1 cells (90).
SARM1 has shown to have different roles in the MAPK pathway (68) (92). SARM1 has been
shown to activate ASK to phosphorylate MKK4, which goes on to activate JNK (68). Knocking
out MKK4 in mice has been shown to reduce axonal degeneration (68). Pathways that could
affect SARM1 can also influence inflammation, like PHR (positive regulator) and kinase AKT
(negative regulator) could be researched in the context of SARM1 to clarify SARM1 impact
(68). PHR loss has been shown to protect axons (68). AKT is known to be an inhibitor of MKK4
(68). On the other hand, in a study by Peng et Al., SARM1 has been shown to result in
downregulation of the MAPK pathway through inhibition of TRIF and MyD88 activation of AP-
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1 (92). As a result, p38 declined with SARM1 overexpression (92). Further research on the
nature of SARM1 in inflammation in a different context will be critical.
Research has shown that SARM1 could function in a process called “Sarmoptosis,” which is
different from apoptosis because it does not depend on caspase activation (68). This complicated
process is of interest because some methods that work to prevent apoptosis, such as Bcl-XL
overexpression and caspase inhibitors, do not prevent SARM-1 mediated neuronal death (68).
Finding inhibitors for the pathway could be beneficial in maintaining axonal integrity. Ca2+
influx could be another avenue to explore as well. SARM1 is necessary for mitochondrial
accumulation and subsequent dysfunction in axon metabolism (79). Also, Ca2+ accumulation, as
stated before, result in calpain activation and cytoskeleton breakdown (52) (60) (63) (68). Using
mitochondrial retention assays for calcium can help quantify this effect in vitro.
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